Scancell Holdings (AIM) Names Dr. Phil L'Huillier as CEO, Boosting Development Expertise

October 23, 2024 12:49 PM AEDT | By Team Kalkine Media

Google News:

Scancell Holdings (AIM) Names Dr. Phil L'Huillier as CEO, Boosting Development Expertise — Image source: Shutterstock

Recent News

EUR/USD poised to rack up more gains as ECB and Fed rate paths set to...

Carney launches ‘One Canadian Economy’ Act to unify trade, approvals

Trump signs orders to enhance drone defenses, support supersonic trave...

US job growth in May tops forecasts, but Macquarie warns cracks are em...

Highlights:

Dr. Phil L'Huillier appointed as CEO of Scancell (LSE), bringing extensive biotech expertise.

Current CEO, Professor Lindy Durrant, transitions to chief scientific officer and continues on the board.

Scancell is expecting significant data from its SCIB1 cancer immunotherapy trial by the end of this year.

Scancell Holdings PLC (LSE:SCLP), a company specializing in cancer immunotherapy, has appointed Dr. Phil L'Huillier as its new chief executive officer, bringing significant expertise in company development and biotech growth. According to Panmure Liberum, an investment bank, L'Huillier’s appointment will strengthen Scancell’s transition to its next phase of clinical and commercial growth, enhancing the company's already robust scientific foundation.

L'Huillier comes with extensive experience in the biotech sector, having led CatalYm GmbH through pivotal clinical trials and secured over $200 million in funding. He has also contributed to the growth and success of several biotech startups, including Achilles Therapeutics and Blink Therapeutics, making him a valuable addition to Scancell’s leadership team.

Lindy Durrant, the current CEO and Scancell’s founder, will remain on the board in her role as chief scientific officer. She will work alongside L'Huillier to ensure the company continues to advance its clinical programmes. Durrant has overseen the development of Scancell’s immunotherapy treatments, including the SCIB1 cancer immunotherapy trial, from which key data is expected by the end of this year.

Panmure Liberum has reiterated its confidence in Scancell, pointing to the upcoming trial results and the company’s solid development trajectory. The firm highlighted L'Huillier's proven ability to navigate clinical challenges and secure funding, positioning him to lead Scancell through its next growth stage.

Scancell’s stock price saw an 11% rise following the announcement, reaching 15p, though it remains below Panmure Liberum’s target valuation of 23p. The City has responded positively to the leadership change, viewing L'Huillier’s appointment as a strategic move to propel Scancell forward in the biotech and immunotherapy space.

As the company prepares for critical trial data and progresses with its therapeutic programmes, the leadership team is focused on pushing Scancell toward new milestones in cancer treatment development.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.